Amundi’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
VCM
VPM
Amundi's BMY Position: Q1 2026 in Review
Amundi increased its Bristol-Myers Squibb (BMY) stake by 11% in Q1 2026, buying an estimated $37.5M and bringing the position to 6,673,998 shares worth $405M. The position accounts for 0.11% of the portfolio, ranked #164.
Amundi first reported a position in BMY in Q2 2021 and has held it in 20 quarters since. The position peaked at $608M in Q4 2022. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Amundi held 6,673,998 shares of Bristol-Myers Squibb worth $405M as of Q1 2026.
- Amundi bought 642,539 Bristol-Myers Squibb shares in Q1 2026, an estimated $37.5M.
- Bristol-Myers Squibb made up 0.11% of Amundi's portfolio in Q1 2026, its #164 holding.
- Amundi first reported a position in Bristol-Myers Squibb in Q2 2021 and has held it in 20 quarters since.
- Amundi's Bristol-Myers Squibb position peaked at $608M in Q4 2022.
- 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.